|By Marketwired .||
|May 29, 2014 02:17 PM EDT||
IRVINE, CA -- (Marketwired) -- 05/29/14 -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase®, and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that it had been featured in a report on Dental Tribune's website.
The report, titled "Rimini show confirms that the future of dentistry is digital," cited BIOLASE as an example of a complete Digital Dental Solution provider. The article mentioned the efforts of BIOLASE in developing its Total Technology Solution. Dental Tribune reported, "In addition to its complete range of dental lasers, the US dental technology company now offers sophisticated imaging equipment and CAD/CAM solutions, such as the GALAXY BioMill System, which allows digital fabrication of restorations chair side."
In an article that also featured Henry Schein's ConnectDental pavilion, Sirona's Digital Dental Academy, and a new dental application for Google Glass, Federico Pignatelli, BIOLASE's CEO, was quoted as saying "The adoption cycle of new technologies is growing increasingly shorter and more advanced technologies like the WaterLase will rapidly find their way into dental practices. Dentists that do not upgrade their conventional equipment will likely begin to lose patients, become uncompetitive and lag behind."
Dental Tribune International CEO and publisher Torsten R. Oemus echoed this sentiment, "Turning dental offices into high-tech playgrounds is indeed becoming a global trend, which reaps rewards for patients and dentists alike. Technology is what differentiates a modern dental office from a conventional one, increases patient flow, and advances diagnostic and treatment outcomes, which ultimately leads to increased revenues."
The complete report is available on line at http://www.dental-tribune.com/articles/news/europe/18455_rimini_show_confirms_that_the_future_of_dentistry_is_digital.html.
About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 25,500 laser systems. Other laser products under development address ophthalmology and other medical and consumer markets.
For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTub
BIOLASE®, WaterLase®, and Total Technology Solution are registered trademarks or trademarks of BIOLASE, Inc.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives, product introductions and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors affecting BIOLASE's business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.
For further information, please contact:
Porter, LeVay & Rose, Inc.
Jul. 26, 2016 01:45 PM EDT Reads: 1,988
Jul. 26, 2016 12:30 PM EDT Reads: 1,576
Jul. 26, 2016 11:45 AM EDT Reads: 547
Jul. 26, 2016 10:45 AM EDT Reads: 1,715
Jul. 26, 2016 10:37 AM EDT Reads: 278
Jul. 26, 2016 10:15 AM EDT Reads: 1,179
Jul. 26, 2016 10:00 AM EDT Reads: 986
Jul. 26, 2016 09:45 AM EDT Reads: 934
Jul. 26, 2016 09:45 AM EDT Reads: 765
Jul. 26, 2016 09:45 AM EDT Reads: 333
Jul. 26, 2016 09:30 AM EDT Reads: 1,076
Jul. 26, 2016 09:15 AM EDT Reads: 1,010
Jul. 26, 2016 09:02 AM EDT Reads: 242
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
Jul. 26, 2016 09:00 AM EDT Reads: 1,694
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
Jul. 26, 2016 09:00 AM EDT Reads: 1,956